.Merck trumps incomes assumptions, rears sales outlook on sturdy demand for best drugs like Keytruda CNBCMerck & Co. (MRK United States) Defeats Revenue Estimates as Keytruda Purchases Growth BloombergMerck Sell: Pharma Giant Posts Strong Outcomes, Yet Outlook Tumbles Short Entrepreneur's Business DailyMerck Announces Second-Quarter 2024 Financial Results Yahoo FinanceMerck beats earnings as well as purchases requirements amidst Keytruda strong point, but provides mixed full-year expectation MarketWatch.